Table 3.
RFS | OS | |||
---|---|---|---|---|
HR* (95% CI†) | p | HR (95% CI) | p | |
Age | ||||
≤ 50 years | 1.61 (0.64–4.02) | 0.310 | 3.14 (0.80–12.40) | 0.102 |
> 50 years | Ref | |||
BC ‡ Subtype | ||||
ER+/HER2-§‖ | Ref | |||
HER2+ | 0.94 (0.30–2.92) | 0.914 | 0.96 (0.16–5.94) | 0.965 |
TNBC¶ | 3.77 (1.70–11.90) | 0.023 | 8.10 (1.84–35.60) | 0.006 |
Pathologic CR # | ||||
Yes | Ref | |||
No | 2.34 (0.64–8.54) | 0.197 | 3.90 (0.47–32.21) | 0.207 |
*HR = hazard ratio, †CI = confidence interval, ‡BC = breast cancer, §ER = estrogen receptor, ‖HER2 = human epidermal growth factor receptor-2, ¶TNBC = triple negative breast cancer, #CR = complete response